Mitral valve surgery for MR after AVSD repair yielded an early mortality rate of 2.2% and 10-year survival of 86.6%, with similar freedom from reoperation between MVP and MVR.
Cohort (n=46)
Does mitral valvuloplasty compared to mitral valve replacement improve outcomes in patients with significant mitral regurgitation after repair of atrioventricular septal defects?
Mitral valve surgery for significant MR after AVSD repair yields acceptable overall survival and clinical improvement, with MVP showing similar freedom from reoperation as MVR but avoiding the high rate of complete heart block seen with MVR.
BACKGROUND: Mitral regurgitation (MR) represents the principal indication for reoperation in patients after repair of atrioventricular septal defects (AVSD). Reports of mitral valvuloplasty (MVP) in such patients are few; the alternative, mitral valve replacement (MVR), necessitates commitment to future valve replacement and long-term anticoagulation. We sought to determine the outcome of those patients who underwent either MVP or MVR between January 1, 1988, and December 31, 1998, for significant MR after repair of AVSD. Furthermore, we sought to identify (a) morphological predictors necessitating MVR, and (b) predictors of future reoperation within the MVP group. METHODS AND RESULTS: Retrospective review of clinical, operative, and echocardiographic data were performed. There were 46 patients identified (37 MVP and 9 MVR). The median age at initial AVSD repair was 0.6 years, and the age at subsequent mitral valve operation was 2.8 years. The early postoperative mortality rate was 2.2%, and survival at 1 and 10 years was 89.9% and 86.6%, respectively. A high rate of complete heart block was noted within the MVR group (37.5%). Freedom from later mitral valve reoperation for both groups was similar. No significant morphological predictors necessitating MVR were found. Predictors of reoperation within the MVP group included the presence of moderate or worse MR in the early postoperative period. In both groups New York Heart Association class, degree of MR, growth, and ventricular volumes improved. CONCLUSIONS: Mitral valve surgery significantly improves clinical status, with a sustained improvement in ventricular chamber size. MR can be successfully managed in patients after repair of AVSD independent of morphological type. Overall survival is acceptable, and further reoperation within the MVP group is influenced by early outcome of repair.
Moran et al. (Tue,) conducted a cohort in Mitral regurgitation after repair of atrioventricular septal defects (n=46). Mitral valvuloplasty (MVP) vs. Mitral valve replacement (MVR) was evaluated on Early postoperative mortality and long-term survival. Mitral valve surgery for MR after AVSD repair yielded an early mortality rate of 2.2% and 10-year survival of 86.6%, with similar freedom from reoperation between MVP and MVR.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: